[
    [
        {
            "time": "",
            "original_text": "凯莱英：董事及高管拟减持不超过13.73万股 拟减持股份",
            "features": {
                "keywords": [
                    "凯莱英",
                    "董事",
                    "高管",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "凯莱英：董事及高管拟减持不超过13.73万股 拟减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：部分董事及高管拟合计减持不超13.727万股 拟减持股份",
            "features": {
                "keywords": [
                    "凯莱英",
                    "董事",
                    "高管",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：部分董事及高管拟合计减持不超13.727万股 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)董事张达等拟合计减持不超13.73万股 拟减持股份",
            "features": {
                "keywords": [
                    "凯莱英",
                    "董事",
                    "张达",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)董事张达等拟合计减持不超13.73万股 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英：部分高级管理人员计划减持公司股份不超过13.7万股 拟减持股份",
            "features": {
                "keywords": [
                    "凯莱英",
                    "高级管理人员",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "凯莱英：部分高级管理人员计划减持公司股份不超过13.7万股 拟减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "注意！凯莱英：股东计划减持公司股份不超过约14万股 拟减持股份",
            "features": {
                "keywords": [
                    "凯莱英",
                    "股东",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "注意！凯莱英：股东计划减持公司股份不超过约14万股 拟减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "粤开医药行业周报 | 国家护航基因治疗产品，坚守医药创新逻辑主线",
            "features": {
                "keywords": [
                    "医药",
                    "基因治疗",
                    "创新",
                    "逻辑主线"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "粤开医药行业周报 | 国家护航基因治疗产品，坚守医药创新逻辑主线",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "生物医药行业周报：国家医保药品目录调整常态化 助力创新药快速放量",
            "features": {
                "keywords": [
                    "生物医药",
                    "医保",
                    "药品目录",
                    "创新药",
                    "放量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "生物医药行业周报：国家医保药品目录调整常态化 助力创新药快速放量",
                "Correlation": 3,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "太平洋-医药行业周报：重点推荐丽珠集团和我武生物【行业研究】",
            "features": {
                "keywords": [
                    "医药",
                    "丽珠集团",
                    "我武生物",
                    "推荐"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "太平洋-医药行业周报：重点推荐丽珠集团和我武生物【行业研究】",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "每日理财观察：7万亿理财市场重磅新规落地",
            "features": {
                "keywords": [
                    "理财",
                    "市场",
                    "新规",
                    "落地"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "每日理财观察：7万亿理财市场重磅新规落地",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 3,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业2021年6月投资月报：6月仍然是较好的窗口期 两条思路配置医药",
            "features": {
                "keywords": [
                    "医药",
                    "投资",
                    "窗口期",
                    "配置"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2021年6月投资月报：6月仍然是较好的窗口期 两条思路配置医药",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]